In Brief: Herbalife And FTC, Reckit And K-Y, DSM In CMO JV

FTC asks Herbalife for answers; Reckitt acquires K-Y; WSP acquisition boosts Omega Proteins; DPx launches in contract manufacturing space; more news In Brief.

The Federal Trade Commission could ask Herbalife Ltd. to explain its business model under an inquiry called a “civil investigative demand” the commission submitted to the multilevel marketer of nutritional and weight loss supplements. The Los Angeles firm on March 12 announced it received a CID from FTC’s Bureau of Competition and “it welcomes the inquiry given the tremendous amount of misinformation in the marketplace.” According to FTC, CIDs are used to obtain existing documents or oral testimony, but also to require a recipient to “file written reports or answers to questions.” The agency contacted Herbalife after Sen. Edward Markey, D-Mass., asked for an inquiry into whether the firm’s business is a pyramid scheme; Markey also asked for an investigation by the Securities and Exchange Commission, which declined to comment. In addition to congressional and regulatory scrutiny, Herbalife for more than a year has been a target for criticism by investor William Ackman, who is short-selling the firm’s stock, betting it eventually would fall to zero, and repeatedly has argued he believes the company is running a pyramid scheme ([A#05140224008]).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

China Plans Clinical Data Protection By Product Category For First Time

 
• By 

After almost seven years, China’s NMPA has once again published draft measures for clinical trial data protection, opening these up to public comments. While specific protection periods by drug category are proposed, some clarifications are still needed.

China Approvals Rise But Conditional-To-Full Conversion Slips

 
• By 

A new annual report from China's CDE shows a rise in overall product approvals but a fall in the transition rate for conditional to full approvals, possibly signalling more stringent requirements.

Elevar/Hengrui’s Second US CRL A Bad Omen For Multiregional Trials In Asia-Dominant Cancers?

 

While CMC glitches linger over a US NDA for Elevar/Hengrui’s novel liver cancer combination following a second complete response letter, the separate issue of underrepresentation of US patients in multiregional trials is looming large after new FDA draft guidance last year.

China Signals Commercial Insurance, Biotech And Foreign-Owned Hospitals As Policy Priorities

 
• By 

The main 2025 policy priorities for China's government as outlined in an annual report will include the strengthening of commercial insurance for innovative drugs and opening up cell and gene therapy and the hospital sector to foreign investment.

More from Asia

Japan Identifies Drugs ‘In Urgent Need’ Of Development

 
• By 

Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By 

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.

Trump Tariffs: Indian Pharma Dodges Bullet, But Sword May Remain

 
• By 

Trump announced a 26% reciprocal tariff on India, but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?